Premium
Preliminary report on the use of danazol in the treatment of endometrial adenomatous hyperplasia
Author(s) -
Terakawa Naoki,
Inoue Masaki,
Shimizu Ikuya,
Ikegami Hiromasa,
Mizutani Takahiro,
Sakata Masahiro,
Tanizawa Osamu,
Matsumoto Keishi
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19881215)62:12<2618::aid-cncr2820621228>3.0.co;2-i
Subject(s) - danazol , medicine , hyperplasia , endometrial biopsy , endometrial hyperplasia , endometrial cancer , gynecology , atypical adenomatous hyperplasia , biopsy , gastroenterology , endometriosis , adenocarcinoma , cancer
Since the authors recently reported that danazol inhibits the growth of human endometrial cancer cells in vitro, a clinical trial was initiated to examine whether danazol can regress adenomatous hyperplasia, a precursor of endometrial adenocarcinoma. Danazol was used for 3 months in the treatment of five patients with a history of hypermenorrhea and irregular uterine bleeding. Within a 9‐month follow‐up period, all patients were symptom‐free, and none of the specimens obtained by endometrial biopsy showed the presence of adenomatous hyperplasia. These findings suggest that danazol has a potential application in the treatment of patients with endometrial adenomatous hyperplasia. A possible mechanism of action of the compound in adenomatous hyperplasia is also discussed.